Biofarma Confident in Strengthening Export Markets, Here's Why

PT Biofarma (Persero) continues to strengthen the export markets for its products across various countries. This effort has been driven by the achievement of Indonesia’s Food and Drug Authority (BPOM), which has successfully attained WHO Listed Authority (WLA) status.

Biofarma’s Chief Executive Officer, Shadiq Akasya, stated that the company has already been exporting some of its products internationally. With the WLA status in place, Biofarma’s business opportunities in developing new healthcare products have expanded significantly, as Indonesian products will now enjoy greater trust from partner countries.

“Secondly, it’s not just about the product, but also the process. One key aspect is clinical trials, which from the outset are supervised by BPOM. Clinical trials occur before product registration, following preclinical phases. This creates further opportunities because Biofarma already possesses the necessary facilities and competencies,” Akasya stated during a Health Forum discussing “BPOM Achieves WLA Status, What Benefits for Business Operators?”

Furthermore, Akasya believes that strengthening BPOM’s status will increase acceptance of Biofarma’s polio vaccine products in various other countries. In this context, Biofarma must identify countries with high birth rates as target markets.

He provided an example, noting that Indonesia’s birth rate reaches approximately 4.8 million per year. From this base, vaccines are administered in multiple doses, ranging from one to three doses.

Several countries from Africa and Asia have emerged as promising market potential for Biofarma’s polio vaccine products.